Baxter International Inc. reports news on its global medtech business, which supplies hospitals, physician offices and other care settings with connected solutions, medical devices and advanced injectable technologies. Company updates commonly cover results from continuing operations following the Kidney Care divestiture, portfolio activity in infusion therapies and platforms, surgical tables, smart stretchers, patient-support systems, monitoring tools, and hemostatic and sealing agents.
Baxter announcements also address product introductions such as the IV Verify Line Labeling System, conference showcases for Global Surgical Solutions, Advanced Surgery and Patient Support Systems, annual-meeting matters, executive finance leadership, and foundation partnerships tied to healthcare settings.
Baxter International Inc. (NYSE:BAX) supports interim findings from a study on the nutritional needs of COVID-19 patients in ICU, which highlights the inaccuracies of predictive equations in estimating energy requirements. The study of 22 U.S. patients indicates that patients experienced progressive hypermetabolism and variability in resting energy expenditure (REE) over their ICU stay. Baxter's Q-NRG+ technology aims to address these challenges by providing accurate and personalized nutrition insights, essential for improving patient outcomes.